 These cell signaling molecules regulate inflammation and facilitate the healing process.Vasogen in collaboration with Grupo Ferrer Internacional has regulatory approval to market Celacade as a medical device for the treatment of chronic heart failure in the European Union and Latin America.In the United States the Food and Drug Administration (FDA) has recommended that Vasogen conduct a further confirmatory study to support a pre-market approval filing.